Novoeight HCP Email: “See a Comparison Chart”




Brand: Novoeight (antihemophilic factor), Intravenous Infusion
Parent Company: Novo Nordisk
Drug Type: Prescription
Drug Category: Hematology
Campaign: Post-Launch
Targeting: HCPs
Patient Website: https://www.novoeight.com/
HCP Website: https://www.novoeightpro.com/

Received: Oct 4, 2018 at 12:01 PM

Subject: 1 alternative to Helixate® FS: Novoeight® (Antihemophilic Factor [Recombinant]).

From: Novo Nordisk